Headquartered in Oxford, United Kingdom, and established in 2007, Oxford BioDynamics Plc operates as a biotechnology enterprise. The company's primary focus lies in the discovery and development of biomarkers for the pharmaceutical and biotechnology industries, serving both domestic and international markets, with a significant presence in the United States. Central to its operations is EpiSwitch, a proprietary technology platform. This platform facilitates the identification, evaluation, validation, and continuous monitoring of epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These biomarkers are utilized in various applications, including medical testing kits, predicting disease onset or progression, aiding in diagnosis, and informing treatment approaches. Among its innovative products are the EpiSwitch CiRT, a validated prognostic tool for anticipating patient response to checkpoint inhibitor immunotherapy; the EpiSwitch CST, an advanced blood assay designed to forecast the severity of COVID-19 in adult patients; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome profiling and the identification of new biomarkers.
—
Headquartered in Oxford, United Kingdom, and established in 2007, Oxford BioDynamics Plc operates as a biotechnology enterprise. The company's primary focus lies in the discovery and development of biomarkers for the pharmaceutical and biotechnology industries, serving both domestic and international markets, with a significant presence in the United States. Central to its operations is EpiSwitch, a proprietary technology platform. This platform facilitates the identification, evaluation, validation, and continuous monitoring of epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These biomarkers are utilized in various applications, including medical testing kits, predicting disease onset or progression, aiding in diagnosis, and informing treatment approaches. Among its innovative products are the EpiSwitch CiRT, a validated prognostic tool for anticipating patient response to checkpoint inhibitor immunotherapy; the EpiSwitch CST, an advanced blood assay designed to forecast the severity of COVID-19 in adult patients; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome profiling and the identification of new biomarkers.
—
Daily adjusted close
Headquartered in Oxford, United Kingdom, and established in 2007, Oxford BioDynamics Plc operates as a biotechnology enterprise. The company's primary focus lies in the discovery and development of biomarkers for the pharmaceutical and biotechnology industries, serving both domestic and international markets, with a significant presence in the United States. Central to its operations is EpiSwitch, a proprietary technology platform. This platform facilitates the identification, evaluation, validation, and continuous monitoring of epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These biomarkers are utilized in various applications, including medical testing kits, predicting disease onset or progression, aiding in diagnosis, and informing treatment approaches. Among its innovative products are the EpiSwitch CiRT, a validated prognostic tool for anticipating patient response to checkpoint inhibitor immunotherapy; the EpiSwitch CST, an advanced blood assay designed to forecast the severity of COVID-19 in adult patients; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome profiling and the identification of new biomarkers.